Extensions

The following information addresses patent term adjustments (PTA), patent term extensions (PTE), continuation applications, divisional applications, related family members, and the projected expiration date for US Patent 12138276.

Patent Term Adjustment (PTA) and Patent Term Extension (PTE)

The provided text does not explicitly state the amount of Patent Term Adjustment (PTA) granted to US Patent 12138276. PTA is calculated by the USPTO to compensate for certain administrative delays during patent prosecution. The PTA determination is typically provided with the Issue Notification Letter prior to the issue date and is indicated on the face of the patent.

Similarly, the provided text does not indicate any Patent Term Extension (PTE) for US Patent 12138276. PTE is usually associated with delays in regulatory review (e.g., FDA approval) for products embodying the patented invention.

Continuation and Divisional Applications

The patent text indicates that US12138276B2 has an application number US18/655,793 and claims priority to US18/655,793 on 2024-05-06 and to US18/909,368 on 2024-10-08. This suggests a chain of priority. For applications filed on or after June 8, 1995, the patent term is 20 years from the filing date of the earliest application for which a benefit is claimed under 35 U.S.C. 120, 121, 365(c), or 386(c).

The relationship between US12138276 (which issued from application US18/655,793) and US18/909,368 is unclear from the provided text, but it suggests they are related family members, potentially through continuation or divisional applications. A continuation application is filed during the pendency of a prior application and shares the same disclosure, while a divisional application results from a restriction requirement during examination. A continuation-in-part application would involve new matter.

Related Family Members

US Patent 12138276B2 is part of a larger intellectual property portfolio for Enveric Biosciences' EVM301 series of molecules. Enveric Biosciences has announced other issued U.S. Patents supporting its EVM301 series, bringing the total number of issued patents to 11 as of December 2, 2024. For example, US Patent No. 12,133,856 was issued around the same time and expands the range of protection for multi-substituent and halogenated psilocybin derivative compounds and pharmaceutical formulations, respectively. More recently, Enveric received U.S. Patent No. 12,577,232 on March 17, 2026, also covering its EVM301 Series, including chemical compounds, pharmaceutical drug formulations, and methods for treating brain neurological disorders.

The patent also claims a priority date of 2020-09-01.

Projected Expiration Date

The patent's filing date is 2024-05-06, and its priority date is 2020-09-01. For applications filed on or after June 8, 1995, the term of a patent generally ends 20 years from the filing date of the earliest application for which a benefit is claimed (the priority date).

Therefore, without any PTA or PTE, the base expiration date would be 20 years from the priority date of 2020-09-01.

Base Expiration Date: September 1, 2040.

However, the Google Patents information indicates an "Anticipated expiration" date of 2041-09-01. This suggests that there might be a Patent Term Adjustment (PTA) of approximately one year. The USPTO does not calculate expiration dates for patents, but provides tools and guidance for estimating them, taking into account factors like PTA, PTE, and terminal disclaimers. The "Anticipated expiration" date provided by Google Patents typically already incorporates any calculated PTA.